Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.
Take two mins to learn more
Expert-led, well-backed team: Founded by strong clinical and technical people, supported by an experienced medtech board and advisors.
Novel glioblastoma technology: GRACE is an implantable device tackling major ‘Quality of Life’ and dosing issues—outshining outdated external EFTs.
Large ($4.7B) market, growing fast: Glioblastoma market set to grow 18% by 2028 - GRACE targets a multibillion-dollar opportunity.
Defensive IP: Two patents at PCT stage, with strong tech differentiation and expansion plans into other cancers.
Clear exit path: Strong M&A/IPO potential with targets like Medtronic or J&J - precedents show high-value, high-multiple deals.

